Tonix Pharmaceuticals Holding Corp. Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Subsidiary, Sale of Stock [Line Items]
Warrants exercise price (in dollars per share)	$ 0.57	$ 0.57
Issuance of common stock in January 2021 [Member]
Subsidiary, Sale of Stock [Line Items]
Price per share	$ 0.80
Transactional expenses	$ 3,096
Issuance of common stock in February 2021 [Member]
Subsidiary, Sale of Stock [Line Items]
Price per share	$ 1.20
Transactional expenses	$ 5,002
Issuance of common stock under At-the-market offering [Member]
Subsidiary, Sale of Stock [Line Items]
Transactional expenses	2,332	$ 2,304
Issuance of common stock under 2021 Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Transactional expenses	$ 75
Issuance of Series B Convertible preferred stock and common stock warrants in February 2020 [Member]
Subsidiary, Sale of Stock [Line Items]
Price per share		$ 1,000.00
Transactional expenses		$ 711
Issuance of common stock and common stock warrants in February 2020 [Member]
Subsidiary, Sale of Stock [Line Items]
Transactional expenses		292
Issuance of common stock in March 2020 [Member]
Subsidiary, Sale of Stock [Line Items]
Transactional expenses		1,221
Issuance of common stock in July 2020 [Member]
Subsidiary, Sale of Stock [Line Items]
Transactional expenses		$ 829